255 related articles for article (PubMed ID: 38153418)
1. Iron chelation improves ineffective erythropoiesis and iron overload in myelodysplastic syndrome mice.
An W; Feola M; Levy M; Aluri S; Ruiz-Martinez M; Sridharan A; Fibach E; Zhu X; Verma A; Ginzburg Y
Elife; 2023 Dec; 12():. PubMed ID: 38153418
[TBL] [Abstract][Full Text] [Related]
2. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.
Shenoy N; Vallumsetla N; Rachmilewitz E; Verma A; Ginzburg Y
Blood; 2014 Aug; 124(6):873-81. PubMed ID: 24923296
[TBL] [Abstract][Full Text] [Related]
3. Iron overload in myelodysplastic syndromes (MDS).
Gattermann N
Int J Hematol; 2018 Jan; 107(1):55-63. PubMed ID: 29177643
[TBL] [Abstract][Full Text] [Related]
4. Unraveling the mechanisms behind iron overload and ineffective hematopoiesis in myelodysplastic syndromes.
Angelucci E; Cianciulli P; Finelli C; Mecucci C; Voso MT; Tura S
Leuk Res; 2017 Nov; 62():108-115. PubMed ID: 29054020
[TBL] [Abstract][Full Text] [Related]
5. [Myelodysplastic syndromes and iron metabolism].
Kawabata H
Rinsho Ketsueki; 2018; 59(10):2042-2049. PubMed ID: 30305507
[TBL] [Abstract][Full Text] [Related]
6. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
[TBL] [Abstract][Full Text] [Related]
7. Iron overload and chelation therapy in myelodysplastic syndromes.
Temraz S; Santini V; Musallam K; Taher A
Crit Rev Oncol Hematol; 2014 Jul; 91(1):64-73. PubMed ID: 24529413
[TBL] [Abstract][Full Text] [Related]
8. [Study of abnormal iron metabolism parameters and iron overload in patients with myelodysplastic syndromes].
Song LL; Zheng QQ; Xiao C; Guo J; Wu D; Su JY; Zhou LY; Chang CK
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):903-907. PubMed ID: 27801326
[TBL] [Abstract][Full Text] [Related]
9. When is iron overload deleterious, and when and how should iron chelation therapy be administered in myelodysplastic syndromes?
Steensma DP; Gattermann N
Best Pract Res Clin Haematol; 2013 Dec; 26(4):431-44. PubMed ID: 24507819
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of deferasirox and deferiprone in the treatment of iron overload in patients with myelodysplastic syndromes.
Cermak J; Jonasova A; Vondrakova J; Cervinek L; Belohlavkova P; Neuwirtova R
Leuk Res; 2013 Dec; 37(12):1612-5. PubMed ID: 23937987
[TBL] [Abstract][Full Text] [Related]
11. Iron Overload in Myelodysplastic Syndromes: Pathophysiology, Consequences, Diagnosis, and Treatment.
Lyle L; Hirose A
J Adv Pract Oncol; 2018; 9(4):392-405. PubMed ID: 30719392
[TBL] [Abstract][Full Text] [Related]
12. EnvIRONmental Aspects in Myelodysplastic Syndrome.
Petzer V; Theurl I; Weiss G; Wolf D
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34068996
[TBL] [Abstract][Full Text] [Related]
13. Iron overload in patients with myelodysplastic syndromes: An updated overview.
Moukalled NM; El Rassi FA; Temraz SN; Taher AT
Cancer; 2018 Oct; 124(20):3979-3989. PubMed ID: 29905937
[TBL] [Abstract][Full Text] [Related]
14. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
Leitch HA
Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
[TBL] [Abstract][Full Text] [Related]
15. Serum iron metabolism and erythropoiesis in patients with myelodysplastic syndrome not receiving RBC transfusions.
Cui R; Gale RP; Zhu G; Xu Z; Qin T; Zhang Y; Huang G; Li B; Fang L; Zhang H; Pan L; Hu N; Qu S; Xiao Z
Leuk Res; 2014 May; 38(5):545-50. PubMed ID: 24598841
[TBL] [Abstract][Full Text] [Related]
16. Iron overload in myelodysplastic syndromes: diagnosis and management.
List AF
Cancer Control; 2010 Jan; 17 Suppl():2-8. PubMed ID: 20125080
[TBL] [Abstract][Full Text] [Related]
17. Observational Monitoring of Patients with Aplastic Anemia and Low/Intermediate-1 Risk of Myelodysplastic Syndromes Complicated with Iron Overload.
Du Y; Long Z; Chen M; Han B; Hou B; Feng F
Acta Haematol; 2017; 138(2):119-128. PubMed ID: 28866669
[TBL] [Abstract][Full Text] [Related]
18. Impact of iron overload in myelodysplastic syndromes.
Fenaux P; Rose C
Blood Rev; 2009 Dec; 23 Suppl 1():S15-9. PubMed ID: 20116635
[TBL] [Abstract][Full Text] [Related]
19. SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia.
Vadolas J; Ng GZ; Kysenius K; Crouch PJ; Dames S; Eisermann M; Nualkaew T; Vilcassim S; Schaeper U; Grigoriadis G
Br J Haematol; 2021 Jul; 194(1):200-210. PubMed ID: 33942901
[TBL] [Abstract][Full Text] [Related]
20. Cardiac iron overload in chronically transfused patients with thalassemia, sickle cell anemia, or myelodysplastic syndrome.
de Montalembert M; Ribeil JA; Brousse V; Guerci-Bresler A; Stamatoullas A; Vannier JP; Dumesnil C; Lahary A; Touati M; Bouabdallah K; Cavazzana M; Chauzit E; Baptiste A; Lefebvre T; Puy H; Elie C; Karim Z; Ernst O; Rose C
PLoS One; 2017; 12(3):e0172147. PubMed ID: 28257476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
